186 related articles for article (PubMed ID: 30006753)
21. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy.
Kuniyasu H; Ukai R; Johnston D; Troncoso P; Fidler IJ; Pettaway CA
Clin Cancer Res; 2003 Jun; 9(6):2185-94. PubMed ID: 12796385
[TBL] [Abstract][Full Text] [Related]
22. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
23. Can single positive core prostate cancer at biopsy be considered a low-risk disease?
Yamamoto H; Koie T; Ookubo T; Mitsuzuka K; Narita S; Inoue T; Kawamura S; Kato T; Tochigi T; Tsuchiya N; Habuchi T; Arai Y; Ohyama C
Int Urol Nephrol; 2018 Oct; 50(10):1829-1833. PubMed ID: 30128924
[TBL] [Abstract][Full Text] [Related]
24. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.
Umbas R; Isaacs WB; Bringuier PP; Schaafsma HE; Karthaus HF; Oosterhof GO; Debruyne FM; Schalken JA
Cancer Res; 1994 Jul; 54(14):3929-33. PubMed ID: 7518346
[TBL] [Abstract][Full Text] [Related]
25. Identification and characterization of nodal metastases in prostate cancer patients at high risk for lymph node involvement.
Isebaert S; Haustermans K; Van den Bergh L; Joniau S; Dirix P; Oyen R; Deroose CM; Van Poppel H; Lerut E
Acta Oncol; 2013 Oct; 52(7):1336-44. PubMed ID: 23879650
[TBL] [Abstract][Full Text] [Related]
26. Expression of E-cadherin in primary prostate cancer: correlation with clinical features.
Kuczyk M; Serth J; Machtens S; Bokemeyer C; Bathke W; Stief C; Jonas U
Br J Urol; 1998 Mar; 81(3):406-12. PubMed ID: 9523661
[TBL] [Abstract][Full Text] [Related]
27. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
28. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
Grosset AA; Ouellet V; Caron C; Fragoso G; Barrès V; Delvoye N; Latour M; Aprikian A; Bergeron A; Chevalier S; Fazli L; Fleshner N; Gleave M; Karakiewicz P; Lacombe L; Lattouf JB; van der Kwast T; Trudel D; Mes-Masson AM; Saad F;
PLoS Med; 2019 Jul; 16(7):e1002847. PubMed ID: 31265453
[TBL] [Abstract][Full Text] [Related]
29. Aberrant expression of p63 in adenocarcinoma of the prostate: a radical prostatectomy study.
Giannico GA; Ross HM; Lotan T; Epstein JI
Am J Surg Pathol; 2013 Sep; 37(9):1401-6. PubMed ID: 23774168
[TBL] [Abstract][Full Text] [Related]
30. sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients.
Tsaur I; Thurn K; Juengel E; Gust KM; Borgmann H; Mager R; Bartsch G; Oppermann E; Ackermann H; Nelson K; Haferkamp A; Blaheta RA
J Exp Clin Cancer Res; 2015 May; 34(1):43. PubMed ID: 25967040
[TBL] [Abstract][Full Text] [Related]
31. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis.
Abdollah F; Suardi N; Cozzarini C; Gallina A; Capitanio U; Bianchi M; Sun M; Fossati N; Passoni NM; Fiorino C; Di Muzio N; Karakiewicz PI; Rigatti P; Montorsi F; Briganti A
Eur Urol; 2013 Jun; 63(6):998-1008. PubMed ID: 23122664
[TBL] [Abstract][Full Text] [Related]
32. N-cadherin switching occurs in high Gleason grade prostate cancer.
Jaggi M; Nazemi T; Abrahams NA; Baker JJ; Galich A; Smith LM; Balaji KC
Prostate; 2006 Feb; 66(2):193-9. PubMed ID: 16173043
[TBL] [Abstract][Full Text] [Related]
33. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
34. BRCA1-associated protein 1 expression and prognostic role in prostate adenocarcinoma.
Oh H; Lee YJ; Kang SG; Ahn B; Kim E; Chae YS; Lee Y; Lee JH; Kim CH
Investig Clin Urol; 2020 Mar; 61(2):166-172. PubMed ID: 32158967
[TBL] [Abstract][Full Text] [Related]
35. Relationship between LSD1 expression and E-cadherin expression in prostate cancer.
Wang M; Liu X; Jiang G; Chen H; Guo J; Weng X
Int Urol Nephrol; 2015 Mar; 47(3):485-90. PubMed ID: 25627913
[TBL] [Abstract][Full Text] [Related]
36. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate.
Krupski T; Petroni GR; Frierson HF; Theodorescu JU
Urology; 2000 May; 55(5):743-9. PubMed ID: 10792093
[TBL] [Abstract][Full Text] [Related]
37. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma.
Ho CM; Cheng WF; Lin MC; Chen TC; Huang SH; Liu FS; Chien CC; Yu MH; Wang TY; Hsieh CY
Int J Gynecol Cancer; 2010 Dec; 20(9):1490-7. PubMed ID: 21119364
[TBL] [Abstract][Full Text] [Related]
39. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
Khani F; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas.
Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Lopes CS
Ann Oncol; 2004 Oct; 15(10):1535-42. PubMed ID: 15367415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
